NVCR News and Press, NovoCure Limited From 05/01/20

Axcella Health (NASDAQ: AXLA ) initiated with Buy rating and $10 (115% upside) price target at BTIG Research. More news on: Axcella Health Inc., Viking Therapeutics, Inc., Y-mAbs Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

NovoCure Limited (NVCR) Q1 2020 Earnings Conference Call April 30, 2020 08:00 AM ET Company Participants Ashley Cordova - Senior Vice President of Finance & Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Wilco Groenhuysen - Chi...

The following slide deck was published by NovoCure Limited in conjunction with their 2020 Q1 earnings Read more ...

NovoCure (NASDAQ: NVCR ): Q1 GAAP EPS of $0.04 beats by $0.02 . More news on: NovoCure Limited, Earnings news and commentary, Healthcare stocks news, Read more ...

Quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019 Balance sheet strength allows continued investments in innovation and the advancement of commercial and development priorities ...

EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune fo...

Glioblastoma is the most invasive and malignant type of brain cancer. If untreated, patients survive for a medial duration of merely three to four months from the initial development of tumors. The condition affects more than 27,000 adults in North America annually. Since 2015, Novocure (NAS...

Inspire Medical Systems (NYSE: INSP ) initiated with Overweight rating and $74 (19% upside) price target at Piper Sandler. More news on: Inspire Medical Systems, Inc., Prevail Therapeutics Inc., Stereotaxis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

BioNano Genomics (NASDAQ: BNGO ) initiated with Outperform rating and $1.50 (443% upside) price target at Oppenheimer. Shares up  19%  premarket. More news on: Bionano Genomics, Inc., NovoCure Limited, Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ,...

Novocure to report first quarter financial results on Thursday, April 30, 2020 Novocure (NASDAQ: NVCR) today provided an update on its response to the global COVID-19 pandemic and an initial evaluation of the impact the pandemic may have on Novocure’s general business operations...